Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia.

To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, quality of life and carer-related outcomes, safety issues such as mortality, adverse effects or withdrawal symptoms.

This is a protocol.

Share/Save